Humanitas Research Hospital | Department Dermatology

Research site

(Unclaimed)

Location

VIa Alessandro Manzoni 56, Rozzano, Lombardia, Italy

Site insights

Top conditions

Top treatments

Durvalumab

Ephedrine

Etilefrine Hydrochloride

Flagyl

PXT002331

Cefuroxime

magnesium oxide

Macrogol 4000

Meropenem

Metformin

Parent organization

This site is a part of Humanitas Research Hospital

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 70 total trials

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will ass...

Active, not recruiting

Myelofibrosis

Solid Tumor, Adult

Drug: Cisplatin

Drug: Pemetrexed

A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis (ENGAGE)

The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or...

Enrolling

Eosinophilic Gastrointestinal Disease

Eosinophilic Gastritis

Drug: Dupilumab Dose 2

Drug: Matching Placebo

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe)

A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced,...

Enrolling

Cholangiocarcinoma

Drug: Ivosidenib Oral Tablet

DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions (DYNAMITE)

The aim of the DYNAMITE study is to investigate the (a) acute procedural and (b) 9-month follow-up performance of DynamX Drug-Eluting Coronary Bioada...

Active, not recruiting

Coronary Artery Disease

Long Lesions Coronary Artery Disease

Device: DynamX Drug-Eluting Coronary Bioadaptor System

Expanded Clinical Study of the Tendyne Mitral Valve System

The purpose of this study is to evaluate the safety and performance of the Tendyne Mitral Valve System in the treatment of severe mitral regurgitatio...

Active, not recruiting

Mitral Valve Regurgitation

Device: Tendyne Mitral Valve System

Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg (PATTERN)

Osteoarthritis (OA) is a degenerative joint disease characterised by chronic pain, degradation and loss of articular cartilage, osteophyte formation...

Enrolling

Osteoarthritis, Knee

Device: KIT BMAC AND at-SVF FIDIA

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)

This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician...

Enrolling

Cholangiocarcinoma

Drug: Physician's Choice

Drug: Tinengotinib 8 mg

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms